When was MannKind Corp founded?

MannKind Corp was founded in 1991 and raised its 1st funding round 13 years after it was founded.

Where is MannKind Corp located?

MannKind Corp is headquartered in Los Angeles, United States. It is registered at 30930 Russell Ranch Road Suite 300 Westlake Village, CA 91362.

How many employees does MannKind Corp have?

As of Sep 30, 2026, the latest employee count at MannKind Corp is 859.

Is MannKind Corp a funded company?

MannKind Corp is a funded company, having raised a total of $50M across 8 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Jan 2004.

When was the latest funding round of MannKind Corp?

MannKind Corp's latest funding was a $***** Post IPO round on Mar 01, 2021, with participation from 0 investor.

What is the annual revenue of MannKind Corp?

Annual revenue of MannKind Corp is between $100M and $500M as on Dec 31, 2025

Where does MannKind Corp rank among its competitors?

MannKind Corp ranks 2nd amongst 116 active competitors, of which 31 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Sernova, which secured $345K in Oct, 2025.

Who are the top competitors of MannKind Corp?

MannKind Corp's top competitors include Rhythm Pharmaceuticals, Corcept and Impel NeuroPharma. Among them, Sernova secured the most recent funding round in October, 2025.

MannKind Corp - 2026 Company Profile, Funding, Competitors & Financials

Company Details

MannKind Corporation focuses on the discovery, development, and commercialization of a variety of therapeutic products through its proprietary drug delivery technology. The company's Technosphere formulation technology uses Technosphere Particles for pulmonary delivery of small molecules, peptides, and proteins directly by inhalation and thus helps in rapid drug absorption, bypassing the liver and also in enhancing bioavailability. The dry powder formulations are made with FDA approved excipients. The company also has proprietary products for inhalation profiling and single multi-use inhalers. The company's lead product includes Afrezza (inhalable ultra-rapid-acting insulin).

Website: mannkindcorp.com
Social
Registered Address: 30930 Russell Ranch Road Suite 300 Westlake Village, CA 91362

Key Metrics

Founded Year

1991

Location

Los Angeles, United States

Stage

Public

Total Funding

$50M in 8 rounds

Latest Funding Round

Post IPO, Mar 01, 2021, $*****

Investors

Colt Ventures & 2 more

Ranked

2^nd among 116 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

859 as on Sep 30, 2026

Investment & Acquisitions

scPharmaceuticals & 2 more

Similar Companies

Rhythm Pharmaceuticals & 144 more

Exit Details

Public

View MannKind Corp's full profile

MannKind Corp is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Mannkind Corp CIN: 899460 , United States, Active		$100M - $500M (As on Dec 31, 2025)	-	-
Mannkind Corporation CIN: 13-3607736 , United States, Active	Feb 13, 1991	-	349 (As on Dec 31, 2021)	-

MannKind Corp got listed on Jul 28, 2004.

Click here to take a look at MannKind Corp's IPO in detail

MannKind Corp has raised a total funding of $50M over 8 rounds. Its first funding round was on Jan 2004. MannKind Corp has 3 institutional investors.

Here is the list of recent funding rounds of MannKind Corp:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 01, 2021	8448760	Post IPO	1224682	5694591	7518352	3860180
Mar 12, 2018	3558338	Post IPO	5709473	2124720	5323683	5402299
Jul 01, 2013	9797834	Venture Debt	9406114	4134707	9943883	Deerfield

Access funding benchmarks and valuations. Sign up today!

View details of MannKind Corp's funding rounds and investors

MannKind Corp's employee count trend

MannKind Corp has 859 employees as of Sep 26. Here is MannKind Corp's employee count trend over the years:

Uncover MannKind Corp's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MannKind Corp include Rhythm Pharmaceuticals, Corcept and Impel NeuroPharma. Here is the list of Top 10 competitors of MannKind Corp, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
2nd	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Ignite 500 & 1 others	71/100
3rd	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Longitude Capital, Cornerstone Capital & 7 others	68/100
4th	Impel NeuroPharma 2008, Seattle (United States), Public	Developer of an intranasal drug delivery technology for CNS diseases	$120M	VenBio, Norwest & 7 others	63/100
5th	Genfit 1999, Loos (France), Public	Therapeutics for cardiometabolic and neurodegenerative diseases.	-	Eiffel Investment Group, Ridgeback Capital Management ... & 2 others	59/100
6th	89bio 2018, San Francisco (United States), Acquired	Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders	$60M	Longitude Capital, Orbimed & 3 others	58/100
7th	Beyond Air 2011, Garden City (United States), Public	Developer of therapeutics for multiple diseases	-	Collage Venture Partners, Cystic Fibrosis Foundation ... Read more	57/100
8th	Sernova 1998, London (Canada), Public	Regenerative medicine to deliver proteins and hormones for disease treatment	-	National Research Council Canada, Evotec & 1 others	57/100
9th	Alexza 2000, Mountain View (United States), Public	Developer of products for the treatment of acute and intermittent conditions	$97M	Versant Ventures, Frazier Healthcare Partners ... & 16 others	57/100
10th	Verdiva Bio 2024, London (United Kingdom), Series A	Developer of oral and injectable peptide therapies for metabolic diseases	$411M	General Atlantic, Forbion & 5 others	56/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on MannKind Corp's competitors? Click here to see the top ones

MannKind Corp has acquired 3 companies including scPharmaceuticals, V-Go and Qrumpharma. MannKind Corp has not made any investments as of now.

Here is the list of its acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Aug 25, 2025	Acquisition	scPharmaceuticals	2013	Lexington (United States)
May 17, 2022	Acquisition	V-Go	2007	Denmark
Dec 07, 2020	Acquisition	Qrumpharma	2014	Doylestown (United States)